Clinical Trials

A Phase 1, Open-Label, Multicenter, Safety Study of Nivolumab (BMS-936558) in Combination with nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or nab-Paclitaxel in Recurrent Metastatic Breast Cancer


Study ID
Celgene ABI-007-ST-001

NCT Number
NCT02309177 (Click on the NCT number for more information about the trial)

Research Study Number
00005397

Principle Investigator
Dr. Martin Gutierrez

Phase
I

Sponsor
Celgene


Other protocol defined inclusion/exclusion criteria could apply If you are a physician and would like more details about this study, please contact us at JTCCResearch@HackensackMeridian.org

Apply Now